Herpesvirus Manufacturing
Specialised services for Herpesvirus–based vectors, for use in gene therapies, oncolytic therapies and vaccines.
Specialised services for Herpesvirus–based vectors, for use in gene therapies, oncolytic therapies and vaccines.
The large size & fragile enveloped structure of Herpesviruses makes sterile filtration impractical and therefore requires aseptic processing from start to finish in specialized BSL-2 facilities.
Specialised development and manufacturing services for Herpesvirus–based vectors, designed for clients with products where viral stability, aseptic processing, and genetic fidelity are critical. With ABL-Ascend you can also expect:
Herpesvirus’s large (~150–200 nm), fragile, enveloped structure makes sterile filtration impractical. Ascend therefore provides:
This ensures clients’ Herpesvirus programs can progress without compromising yield or product safety requirements.
We provide a robust purification train designed around the sensitivity and size of Herpesvirus:
Our DSP team has developed Herpesvirus specific learnings that reduce loss during large scale concentration and minimise shear damage.
– Endotoxin
– Sterility
– Replication Competence
– Adventitious Agents
– Mycoplasma & Mycobacteria
– Process Residuals (HC protein & DNA; nuclease, BSA)
– Aggregation
– Residual DNA Sizing/Identity
– Physical Titer
– Infectious Titer
– Functional Titer
– Capsid ID
– Viral Protein ID
– Vector Genome Integrity
– pH
– Osmolarity
– Appearance
– Extractable Volume
– Subvisible Particles
Please contact us using the form below and a member of our team will be in touch.
"*" indicates required fields